Neuronal defects in a human cellular model of 22q11.2 deletion syndrome.


Journal

Nature medicine
ISSN: 1546-170X
Titre abrégé: Nat Med
Pays: United States
ID NLM: 9502015

Informations de publication

Date de publication:
12 2020
Historique:
received: 27 11 2019
accepted: 30 07 2020
pubmed: 30 9 2020
medline: 29 1 2021
entrez: 29 9 2020
Statut: ppublish

Résumé

22q11.2 deletion syndrome (22q11DS) is a highly penetrant and common genetic cause of neuropsychiatric disease. Here we generated induced pluripotent stem cells from 15 individuals with 22q11DS and 15 control individuals and differentiated them into three-dimensional (3D) cerebral cortical organoids. Transcriptional profiling across 100 days showed high reliability of differentiation and revealed changes in neuronal excitability-related genes. Using electrophysiology and live imaging, we identified defects in spontaneous neuronal activity and calcium signaling in both organoid- and 2D-derived cortical neurons. The calcium deficit was related to resting membrane potential changes that led to abnormal inactivation of voltage-gated calcium channels. Heterozygous loss of DGCR8 recapitulated the excitability and calcium phenotypes and its overexpression rescued these defects. Moreover, the 22q11DS calcium abnormality could also be restored by application of antipsychotics. Taken together, our study illustrates how stem cell derived models can be used to uncover and rescue cellular phenotypes associated with genetic forms of neuropsychiatric disease.

Identifiants

pubmed: 32989314
doi: 10.1038/s41591-020-1043-9
pii: 10.1038/s41591-020-1043-9
pmc: PMC8525897
mid: NIHMS1726998
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

1888-1898

Subventions

Organisme : NIMH NIH HHS
ID : R01 MH094714
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH121075
Pays : United States
Organisme : NIMH NIH HHS
ID : R37 MH060233
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH107800
Pays : United States
Organisme : NIMH NIH HHS
ID : U01 MH115746
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH100900
Pays : United States
Organisme : NIMH NIH HHS
ID : U01 MH115745
Pays : United States
Organisme : Howard Hughes Medical Institute
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH085953
Pays : United States

Références

Sullivan, P. F., Daly, M. J. & O’Donovan, M. Genetic architectures of psychiatric disorders: the emerging picture and its implications. Nat. Rev. Genet. 13, 537–551 (2012).
pubmed: 22777127 pmcid: 4110909
Sanders, S. J. et al. A framework for the investigation of rare genetic disorders in neuropsychiatry. Nat. Med. 25, 1477–1487 (2019).
pubmed: 31548702 pmcid: 8656349
Zinkstok, J. R. et al. Neurobiological perspective of 22q11.2 deletion syndrome. Lancet Psychiatry 6, 951–960 (2019).
pubmed: 31395526 pmcid: 7008533
Murphy, K. C., Jones, L. A. & Owen, M. J. High rates of schizophrenia in adults with velo-cardio-facial syndrome. Arch. Gen. Psychiatry 56, 940–945 (1999).
pubmed: 10530637
Monks, S. et al. Further evidence for high rates of schizophrenia in 22q11.2 deletion syndrome. Schizophr. Res. 153, 231–236 (2014).
pubmed: 24534796
Schneider, M. et al. Psychiatric disorders from childhood to adulthood in 22q11.2 deletion syndrome: results from the International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome. Am. J. Psychiatry 171, 627–639 (2014).
pubmed: 24577245 pmcid: 4285461
Vorstman, J. A. et al. The 22q11.2 deletion in children: high rate of autistic disorders and early onset of psychotic symptoms. J. Am. Acad. Child Adolesc. Psychiatry 45, 1104–1113 (2006).
pubmed: 16926618
Olsen, L. et al. Prevalence of rearrangements in the 22q11.2 region and population-based risk of neuropsychiatric and developmental disorders in a Danish population: a case-cohort study. Lancet Psychiatry 5, 573–580 (2018).
pubmed: 29886042 pmcid: 6560180
Drew, L. J. et al. The 22q11.2 microdeletion: fifteen years of insights into the genetic and neural complexity of psychiatric disorders. Int. J. Dev. Neurosci. 29, 259–281 (2011).
pubmed: 20920576
Karayiorgou, M., Simon, T. J. & Gogos, J. A. 22q11.2 microdeletions: linking DNA structural variation to brain dysfunction and schizophrenia. Nat. Rev. Neurosci. 11, 402–416 (2010).
pubmed: 20485365 pmcid: 2977984
Chun, S. et al. Specific disruption of thalamic inputs to the auditory cortex in schizophrenia models. Science 344, 1178–1182 (2014).
pubmed: 24904170 pmcid: 4349506
Sigurdsson, T., Stark, K. L., Karayiorgou, M., Gogos, J. A. & Gordon, J. A. Impaired hippocampal-prefrontal synchrony in a genetic mouse model of schizophrenia. Nature 464, 763–767 (2010).
pubmed: 20360742 pmcid: 2864584
Fernandez, A. et al. Mitochondrial dysfunction leads to cortical under-connectivity and cognitive impairment. Neuron 102, 1127–1142 e1123 (2019).
pubmed: 31079872 pmcid: 6668992
Demaerel, W. et al. The 22q11 low copy repeats are characterized by unprecedented size and structural variability. Genome Res. 29, 1389–1401 (2019).
pubmed: 31481461 pmcid: 6724673
Pasca, S. P. The rise of three-dimensional human brain cultures. Nature 553, 437–445 (2018).
pubmed: 29364288
Zhao, D. et al. MicroRNA profiling of neurons generated using induced pluripotent stem cells derived from patients with schizophrenia and schizoaffective disorder, and 22q11.2 Del. PLoS ONE 10, e0132387 (2015).
pubmed: 26173148 pmcid: 4501820
Toyoshima, M. et al. Analysis of induced pluripotent stem cells carrying 22q11.2 deletion. Transl. Psychiatry 6, e934 (2016).
pubmed: 27801899 pmcid: 5314118
Lin, M. et al. Integrative transcriptome network analysis of iPSC-derived neurons from schizophrenia and schizoaffective disorder patients with 22q11.2 deletion. BMC Syst. Biol. 10, 105 (2016).
pubmed: 27846841 pmcid: 5111260
Pasca, A. M. et al. Functional cortical neurons and astrocytes from human pluripotent stem cells in 3D culture. Nat. Methods 12, 671–678 (2015).
pubmed: 26005811 pmcid: 4489980
Sloan, S. A., Andersen, J., Pasca, A. M., Birey, F. & Pasca, S. P. Generation and assembly of human brain region-specific three-dimensional cultures. Nat. Protoc. 13, 2062–2085 (2018).
pubmed: 30202107 pmcid: 6597009
Sloan, S. A. et al. Human astrocyte maturation captured in 3D cerebral cortical spheroids derived from pluripotent stem cells. Neuron 95, 779–790 (2017).
pubmed: 28817799 pmcid: 5890820
Yoon, S. J. et al. Reliability of human cortical organoid generation. Nat. Methods 16, 75–78 (2019).
pubmed: 30573846
Pașca, S. P. et al. Using iPSC-derived neurons to uncover cellular phenotypes associated with Timothy syndrome. Nat. Med. 17, 1657–1662 (2011).
pubmed: 22120178 pmcid: 3517299
Sun, Y. et al. A deleterious Nav1.1 mutation selectively impairs telencephalic inhibitory neurons derived from Dravet syndrome patients. eLife 5, e13073 (2016).
pubmed: 27458797 pmcid: 4961470
Cross-Disorder Group of the Psychiatric Genomics Consortium. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet 381, 1371–1379 (2013).
pmcid: 3714010
Moskvina, V. et al. Gene-wide analyses of genome-wide association data sets: evidence for multiple common risk alleles for schizophrenia and bipolar disorder and for overlap in genetic risk. Mol. Psychiatry 14, 252–260 (2009).
pubmed: 19065143
Yasumoto, F. et al. Dopamine receptor 2 regulates L-type voltage-gated calcium channel in primary cultured mouse midbrain neural network. Cell. Mol. Neurobiol. 24, 877–882 (2004).
pubmed: 15672688
Morrow, B. E., McDonald-McGinn, D. M., Emanuel, B. S., Vermeesch, J. R. & Scambler, P. J. Molecular genetics of 22q11.2 deletion syndrome. Am. J. Med. Genet. A 176, 2070–2081 (2018).
pubmed: 30380194 pmcid: 6214629
Sun, Z., Williams, D. J., Xu, B. & Gogos, J. A. Altered function and maturation of primary cortical neurons from a 22q11.2 deletion mouse model of schizophrenia. Transl. Psychiatry 8, 85 (2018).
pubmed: 29666363 pmcid: 5904157
Han, J. et al. The Drosha–DGCR8 complex in primary microRNA processing. Genes Dev. 18, 3016–3027 (2004).
pubmed: 15574589 pmcid: 535913
Gokhale, A. et al. Systems analysis of the 22q11.2 microdeletion syndrome converges on a mitochondrial interactome necessary for synapse function and behavior. J. Neurosci. 39, 3561–3581 (2019).
pubmed: 30833507 pmcid: 6495129
Grove, J. et al. Identification of common genetic risk variants for autism spectrum disorder. Nat. Genet. 51, 431–444 (2019).
pubmed: 30804558 pmcid: 6454898
Pardinas, A. F. et al. Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. Nat. Genet. 50, 381–389 (2018).
pubmed: 29483656 pmcid: 5918692
Demontis, D. et al. Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder. Nat. Genet. 51, 63–75 (2019).
pubmed: 30478444
Parikshak, N. N. et al. Genome-wide changes in lncRNA, splicing, and regional gene expression patterns in autism. Nature 540, 423–427 (2016).
pubmed: 27919067 pmcid: 7102905
Fromer, M. et al. Gene expression elucidates functional impact of polygenic risk for schizophrenia. Nat. Neurosci. 19, 1442–1453 (2016).
pubmed: 27668389 pmcid: 5083142
Krey, J. F. et al. Timothy syndrome is associated with activity-dependent dendritic retraction in rodent and human neurons. Nat. Neurosci. 16, 201–209 (2013).
pubmed: 23313911 pmcid: 3568452
Moore, A. R. et al. Electrical excitability of early neurons in the human cerebral cortex during the second trimester of gestation. Cereb. Cortex 19, 1795–1805 (2009).
pubmed: 19015375
Drew, L. J. et al. Evidence for altered hippocampal function in a mouse model of the human 22q11.2 microdeletion. Mol. Cell Neurosci. 47, 293–305 (2011).
pubmed: 21635953 pmcid: 3539311
Zamponi, G. W., Striessnig, J., Koschak, A. & Dolphin, A. C. The physiology, pathology and pharmacology of voltage-gated calcium channels and their future therapeutic potential. Pharm. Rev. 67, 821–870 (2015).
pubmed: 26362469 pmcid: 4630564
Wheeler, D. G. et al. Ca
pubmed: 22632974 pmcid: 3654514
Schofield, C. M. et al. Monoallelic deletion of the microRNA biogenesis gene Dgcr8 produces deficits in the development of excitatory synaptic transmission in the prefrontal cortex. Neural Dev. 6, 11 (2011).
pubmed: 21466685 pmcid: 3082233
Gritz, S. M. & Radcliffe, R. A. Genetic effects of ATP1A2 in familial hemiplegic migraine type II and animal models. Hum. Genomics 7, 8 (2013).
pubmed: 23561701 pmcid: 3639839
McQuate, A., Latorre-Esteves, E. & Barria, A. A Wnt/calcium signaling cascade regulates neuronal excitability and trafficking of NMDARs. Cell Rep. 21, 60–69 (2017).
pubmed: 28978484
Bassett, A. S. & Chow, E. W. Schizophrenia and 22q11.2 deletion syndrome. Curr. Psychiatry Rep. 10, 148–157 (2008).
pubmed: 18474208 pmcid: 3129332
Seeman, P., Lee, T., Chau-Wong, M. & Wong, K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261, 717–719 (1976).
pubmed: 945467
Kapur, S., Zipursky, R., Jones, C., Remington, G. & Houle, S. Relationship between dopamine D
pubmed: 10739409
Hernandez-Lopez, S. et al. D
pubmed: 11124974 pmcid: 6773013
Gee, S. et al. Synaptic activity unmasks dopamine D
pubmed: 22492051 pmcid: 3352768
Santana, N., Mengod, G. & Artigas, F. Quantitative analysis of the expression of dopamine D
pubmed: 18689859
Perez, M. F., White, F. J. & Hu, X. T. Dopamine D
pubmed: 16885524
Gardner, D. M., Baldessarini, R. J. & Waraich, P. Modern antipsychotic drugs: a critical overview. CMAJ 172, 1703–1711 (2005).
pubmed: 15967975 pmcid: 1150265
Kobrynski, L. J. & Sullivan, K. E. Velocardiofacial syndrome, DiGeorge syndrome: the chromosome 22q11.2 deletion syndromes. Lancet 370, 1443–1452 (2007).
pubmed: 17950858
Chun, S., Bayazitov, I. T., Blundon, J. A. & Zakharenko, S. S. Thalamocortical long-term potentiation becomes gated after the early critical period in the auditory cortex. J. Neurosci. 33, 7345–7357 (2013).
pubmed: 23616541 pmcid: 3679664
Eaton, C. B. et al. Epilepsy and seizures in young people with 22q11.2 deletion syndrome: prevalence and links with other neurodevelopmental disorders. Epilepsia 60, 818–829 (2019).
pubmed: 30977115 pmcid: 6519005
Yu, N., Tucker, K. R., Levitan, E. S., Shepard, P. D. & Canavier, C. C. Implications of cellular models of dopamine neurons for schizophrenia. Prog. Mol. Biol. Transl. Sci. 123, 53–82 (2014).
pubmed: 24560140 pmcid: 4351765
Anwar, I. J., Miyata, K. & Zsombok, A. Brain stem as a target site for the metabolic side effects of olanzapine. J. Neurophysiol. 115, 1389–1398 (2016).
pubmed: 26719086
Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature 511, 421–427 (2014).
pmcid: 4112379
Akam, E. & Strange, P. G. Inverse agonist properties of atypical antipsychotic drugs. Biochem. Pharmacol. 67, 2039–2045 (2004).
pubmed: 15135301
Li, P., Snyder, G. L. & Vanover, K. E. Dopamine targeting drugs for the treatment of Schizophrenia: past, present and future. Curr. Top. Med. Chem. 16, 3385–3403 (2016).
pubmed: 27291902 pmcid: 5112764
Yazawa, M. et al. Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature 471, 230–234 (2011).
pubmed: 21307850 pmcid: 3077925
Birey, F. et al. Assembly of functionally integrated human forebrain spheroids. Nature 545, 54–59 (2017).
pubmed: 28445465 pmcid: 5805137
Barreto-Chang, O. L. & Dolmetsch, R. E. Calcium imaging of cortical neurons using Fura-2 AM. J. Vis. Exp. 9, 1067 (2009).
Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013).
pubmed: 23104886
Li, B. & Dewey, C. N. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics 12, 323 (2011).
pubmed: 21816040 pmcid: 3163565
Oldham, M. C., Langfelder, P. & Horvath, S. Network methods for describing sample relationships in genomic datasets: application to Huntington’s disease. BMC Syst. Biol. 6, 63 (2012).
pubmed: 22691535 pmcid: 3441531
Johnson, W. E., Li, C. & Rabinovic, A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8, 118–127 (2007).
pubmed: 16632515
McKenna, A. et al. The genome analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297–1303 (2010).
pubmed: 20644199 pmcid: 2928508
Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81, 559–575 (2007).
pubmed: 17701901 pmcid: 1950838
Hansen, K. D., Irizarry, R. A. & Wu, Z. Removing technical variability in RNA-seq data using conditional quantile normalization. Biostatistics 13, 204–216 (2012).
pubmed: 22285995 pmcid: 3297825
Korotkevich, G., Sukhov, V. & Sergushichev, A. Fast gene set enrichment analysis. Preprint at bioRxiv 060012 https://www.biorxiv.org/content/10.1101/060012v2 (2019).
Finucane, H. K. et al. Partitioning heritability by functional annotation using genome-wide association summary statistics. Nat. Genet. 47, 1228–1235 (2015).
pubmed: 26414678 pmcid: 4626285
Wu, H., Wang, C. & Wu, Z. PROPER: comprehensive power evaluation for differential expression using RNA-seq. Bioinformatics 31, 233–241 (2015).
pubmed: 25273110
Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139–140 (2010).
pubmed: 19910308
Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies and species. Nat. Biotechnol. 36, 411–420 (2018).
pubmed: 29608179 pmcid: 6700744

Auteurs

Themasap A Khan (TA)

Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.
Program in Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA, USA.

Omer Revah (O)

Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.

Aaron Gordon (A)

Program in Neurogenetics, Department of Neurology, University of California Los Angeles, Los Angeles, CA, USA.

Se-Jin Yoon (SJ)

Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.

Anna K Krawisz (AK)

Department of Neurobiology, Stanford University, Stanford, CA, USA.
Division of Cardiology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.

Carleton Goold (C)

Department of Neurobiology, Stanford University, Stanford, CA, USA.

Yishan Sun (Y)

Department of Neurobiology, Stanford University, Stanford, CA, USA.

Chul Hoon Kim (CH)

Department of Neurobiology, Stanford University, Stanford, CA, USA.
Department of Pharmacology, Yonsei University College of Medicine, Seoul, Republic of Korea.

Yuan Tian (Y)

Program in Neurogenetics, Department of Neurology, University of California Los Angeles, Los Angeles, CA, USA.
Interdepartmental PhD Program in Bioinformatics, University of California Los Angeles, Los Angeles, CA, USA.

Min-Yin Li (MY)

Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.

Julia M Schaepe (JM)

Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.

Kazuya Ikeda (K)

Department of Pediatrics, Stanford University, Stanford, CA, USA.

Neal D Amin (ND)

Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.

Noriaki Sakai (N)

Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.

Masayuki Yazawa (M)

Department of Neurobiology, Stanford University, Stanford, CA, USA.
Columbia Stem Cell Initiative, Department of Rehabilitation and Regenerative Medicine, Department of Molecular Pharmacology and Therapeutics, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA.

Leila Kushan (L)

Department of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, Los Angeles, CA, USA.

Seiji Nishino (S)

Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.

Matthew H Porteus (MH)

Department of Pediatrics, Stanford University, Stanford, CA, USA.

Judith L Rapoport (JL)

National Institute of Mental Health, Child Psychiatry Branch, Bethesda, MD, USA.

Jonathan A Bernstein (JA)

Department of Pediatrics, Stanford University, Stanford, CA, USA.

Ruth O'Hara (R)

Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.

Carrie E Bearden (CE)

Department of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, Los Angeles, CA, USA.
Department of Psychology, University of California Los Angeles, Los Angeles, CA, USA.
Center for Neurobehavioral Genetics, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles, Los Angeles, CA, USA.

Joachim F Hallmayer (JF)

Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.

John R Huguenard (JR)

Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA.

Daniel H Geschwind (DH)

Program in Neurogenetics, Department of Neurology, University of California Los Angeles, Los Angeles, CA, USA.
Department of Human Genetics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Center for Autism Research and Treatment, Semel Institute, University of California Los Angeles, Los Angeles, CA, USA.
Institute of Precision Health, University of California Los Angeles, Los Angeles, CA, USA.

Ricardo E Dolmetsch (RE)

Novartis Institutes for BioMedical Research, Cambridge, MA, USA.

Sergiu P Paşca (SP)

Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA. spasca@stanford.edu.
Stanford Brain Organogenesis Program, Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, USA. spasca@stanford.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH